Chime Biologics Enters into a Strategic Cooperation Agreement with Sumgen Biotech
Wuhan, China, September 24, 2021 – Chime Biologics, a leading CDMO that enables biologics therapeutic development, announced a strategic cooperation agreement with Hangzhou Sumgen Biotechnology Co., Ltd, an innovation-driven biopharmaceutical company dedicated to the development and commercialization of antibodies for cancer and other life-threatening malignancies major diseases, regarding its Bispecific Antibody Project (SG12473).
According to the agreement, Chime Biologics will provide technology transfer and scale-up manufacturing, process characterization, process validation and BLA for Sumgen Biotech’s first bispecific antibody project (SG12473). Sumgen Biotech will make the most of Chime’s expertise in manufacturing commercial batches of cGMP 2000L drug substances, late-stage CMC development and BLA to accelerate the development of SG12473.
Dr. Miao Shiwei, Co-Founder and Senior Vice President of Sumgen Biotech, Dr. Zeng Xianfang, CEO of Chime Biologics, and other representatives of both parties attended the signing ceremony.
Dr. Miao Shiwei from Sumgen Biotech, stated that “As SG12473 is the first bispecific antibody of Sumgen Biotech in the clinical stage, we are very excited to make a strategic partnership with Chime Biologics on such an important project. The philosophy of Chime Biologics that to make biologics meeting international standards accessible to all patients worldwide through technological and manufacturing innovation coincides with that of Sumgen Biotech. That’s why we are sure that the professional technology transfer and BLA experience of Chime Biologics will fuel the smooth marketing of the drug in an efficient and accelerated manner.”
Dr. Zeng Xianfang from Chime Biologics said, “We are very happy to enter into such an important collaboration with Sumgen Biotech, a highly innovative company. To date, we have completed over 30 CDMO projects with zero failure and have supplied drug substances and clinical trial samples to over 20 countries. With a proven track record in terms of quality management, GMP compliance, bioprocess expertise and cost-effectiveness, we will make every effort to support Sumgen Biotech to promote this project. And we wish this important product an earlier marketing.”
About Sumgen Biotech
Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as Sumgen Biotech or the “Company”) is an innovation-driven biopharmaceutical company dedicated to development and commercialization of innovative antibodies for cancer and other life-threatening malignancies. Dr. Lv obtained his bachelor’s degree in Zhejiang University and completed his PhD degree in AMMS. His supervisor, academician Beifen Shen, is a national-renowned immunologist, who laid the foundation of immunology research in China. After graduation, Lv stayed on as assistant of Academician Shen to conduct her research. In 2014, Dr. Lv developed the anti-Ebola antibody MIL77, which successfully cured British female soldiers and received high attention and recognition from the government.
Sumgen holds the belief that technology innovation leads to product innovation. Over the past 5 years, we are led by a professional management team and scientific advisory board including key opinion leaders from research institute, experts at home and abroad highly experienced in biopharmaceutical industry. Early-stage R&D centers located in Beijing with headquarters in Hangzhou. We have successfully built an integrated process covering antibody discovery to scale-up manufacturing and clinical development, and established robust pipeline focusing on oncology with more than 70 patents applications. SG001 entered Phase II stage in 2021, and other ongoing programs steadily move forward such as SG301, SG404, SG12473 and SG2501. Sumgen secured multiple funding rounds from Hankang Capital, China National Biotech Group (CNBG), Addor Capital, Sinowisdom, Cowin Capital, Junchuan Capital, Zheshang Venture Capital and other institutions; established partnership with CSPC for SG001 project. In Mar. 2020, joint venture CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. established to further accelerate the industrialization of Sumgen pipeline assets.
Supported by Governments and institutions, Sumgen Biotech has initiated the GMP Manufacturing Site Construction Project. With a 2-year plan to build a large-scale production base for antibody drugs that complies with international regulations, to rapidly promote the industrialization of several innovative antibodies, and to strive to become an internationally leading, sustainably innovative biopharmaceutical company that provides high-quality Chinese antibodies to patients worldwide.
About Chime Biologics
Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners’ success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health. For more information, please visit www.chimebiologics.com.
